



July 30, 2025

BSE Ltd.
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai 400 001

BSE Scrip Code : 506943

Stock Symbol: JBCHEPHARM

Dear Sir,

Subject: Press Release

Enclosed please find press release the Company proposes to issue on unaudited consolidated financial results for the quarter ended on June 30, 2025.

Kindly take the same on record.

Thanking you,

Yours faithfully,

For J.B. Chemicals & Pharmaceuticals Limited

**Sandeep Phadnis
Vice President - Secretarial
& Company Secretary**

Registered Office:

J.B. Chemicals & Pharmaceuticals Limited,
CIN: L24390MH1976PLC019380
Neelam Centre, 'B' Wing, 4th Floor, Hind Cycle Road,
Worli, Mumbai – 400030, T:+91 22 24822222

Corporate Office:

J.B. Chemicals & Pharmaceuticals Limited,
CIN: L24390MH1976PLC019380
Cnergy IT Park, Unit A, 8th Floor, Appa Saheb Marathe Marg,
Prabhadevi, Mumbai – 400025, T:+91 22 24395200/5500
secretarial@jbpharma.com

www.jbpharma.com



Press Release

JB Pharma records revenue growth of 9% to INR 1094 crores in Q1 FY26 Operating EBITDA* increased by 13% to INR 330 crores Net Profit increases by 14% to INR 202 crores

Mumbai, India; July 30, 2025 – JB Chemicals & Pharmaceuticals Ltd (JB Pharma), one of the fastest growing pharmaceutical companies in India, announced its financial results for the quarter ended 30th June 2025.

Quarterly Financial Performance – Q1 FY26 vs Q1 FY25

JB Pharma recorded revenue of INR 1,094 crores in the first quarter of FY26, registering growth of 9% from INR 1,004 crores in Q1 FY25. Operating EBITDA* (Earnings before Interest, Depreciation and Taxes) increased by 13% to INR 330 crores compared to INR 292 crores in the same quarter last year. Net Profit rose by 14% to INR 202 crores versus INR 177 crores in Q1 FY25.

*Operating EBITDA is after excluding non-cash ESOP charge and one off charges

Commenting on the financial results, **Mr. Nikhil Chopra, CEO and Wholetime Director, JB Pharma stated**

“JB continues to be the fastest growing domestic pharma company amongst top 25 organizations as per IQVIA MAT Jun’25 data. The domestic business recorded approx. 14% value growth. This was driven by acute and chronic segments, including our ophthalmology portfolio. Our major brands & their franchises are also performing well. The CDMO business momentum is likely to sustain in coming quarters. Our Operating EBITDA margins crossed 30% for the first time, which highlights the results of our strategy of focusing on profitable growth.”*

Registered Office:

J.B. Chemicals & Pharmaceuticals Limited,
CIN: L24390MH1976PLC019380
Neelam Centre, 'B' Wing, 4th Floor, Hind Cycle Road,
Worli, Mumbai – 400030, T:+91 22 24822222

Corporate Office:

J.B. Chemicals & Pharmaceuticals Limited,
CIN: L24390MH1976PLC019380
Cnergy IT Park, Unit A, 8th Floor, Appa Saheb Marathe Marg,
Prabhadevi, Mumbai – 400025, T:+91 22 24395200/5500

www.jbpharma.com



GOOD PEOPLE
for GOOD HEALTH

Going forward, we will maintain focus on driving topline growth, cost optimization and organizational efficiencies. I am confident that the organization will continue to perform well, with our domestic and CDMO segments leading the way on growth and profitability. We have all the necessary building blocks in place for sustainable growth in the coming years."

Financial Performance

Q1 FY26 vs Q1 FY25

Particulars (INR Crores)	Q1 FY26	Q1 FY25	YoY Growth
Revenue	1094	1004	9%
Operating EBITDA*	330	292	13%
Op. EBITDA Margin (%)	30.2%	29.0%	
Profit Before Tax	272	240	13%
Profit After Tax	202	177	14%

FY25 vs FY24

Particulars (INR Crores)	FY25	FY24	YoY Growth
Revenue	3918	3484	12%
Operating EBITDA	1087	939	16%
Op. EBITDA Margin (%)	27.7%	27.0%	
Profit Before Tax	887	752	18%
Profit After Tax	660	553	19%

Sales Performance

Q1 FY26 vs Q1 FY25

Particulars (INR Crores)	Q1 FY26	Q1 FY25	YoY Growth
Domestic Formulations	678	595	14%
International Formulations	416	409	2%
Total Revenue	1094	1004	9%

Registered Office:

J.B. Chemicals & Pharmaceuticals Limited,
CIN: L24390MH1976PLC019380
Neelam Centre, 'B' Wing, 4th Floor, Hind Cycle Road,
Worli, Mumbai – 400030, T:+91 22 24822222

Corporate Office:

J.B. Chemicals & Pharmaceuticals Limited,
CIN: L24390MH1976PLC019380
Cnergy IT Park, Unit A, 8th Floor, Appa Saheb Marathe Marg,
Prabhadevi, Mumbai – 400025, T:+91 22 24395200/5500

www.jbpharma.com



GOOD PEOPLE
for **GOOD HEALTH**

FY25 vs FY24

Particulars (INR Crores)	FY25	FY24	YoY Growth
Domestic Formulations	2269	1897	20%
International Formulations	1649	1587	4%
Total Revenue	3918	3484	12%

Key Highlights

Q1 FY26 vs Q1 FY25

- JB Pharma's revenue grew 9% to INR 1094 crores as compared to INR 1004 crores
- Domestic formulations business recorded revenue of INR 678 crores vs INR 595 crores (YoY growth of 14%) driven by good growth in acute including opthal portfolio and the chronic portfolio
- International business revenue declined marginally to INR 283 crores vs INR 290 crores
 - While overall international business remained muted for Q1 FY26, CDMO business registered high single digit growth

Financial Overview Q1 FY26 vs Q1 FY25

- Operating EBITDA improved by 13% to INR 330 crores vs INR 292 crores. Operating EBITDA* margin stood at 30.2% v/s 29.0%
- Gross margins increased to 68.3% as compared to 66.2%
 - Cost optimization efforts, favorable business mix and price growth positively impacted gross margin
- Employee Benefit expenses grew by 16% to INR 194 crores
 - ESOP cost was at INR 14 crores v/s INR 12 crores
- Other expenses increased by 16% to INR 252 crores primarily on account of one-off charges due to the proposed merger scheme
- Depreciation increased marginally by 5% to INR 43 crores v/s INR 41 crores
- Net Profit improved by 14% to INR 202 crores v/s INR 177 crores



Domestic Business Q1 FY26 vs Q1 FY25

- Domestic business revenue registered YoY growth of 14% to INR 678 crores vs INR 595 Crores
- As per IQVIA MAT Jun'25 data, JB is the fastest growing company at 13% among the top 25 companies in the country
- As per IQVIA Q1 FY26 data, JB Pharma recorded YoY growth of 13% vs IPM growth of 9%
 - Chronic portfolio registered growth of 15% in Q1 FY26 (IQVIA data)
 - Acute portfolio registered YoY growth of 12% in Q1 FY26 (IQVIA data)
 - Ophthalmology portfolio clocked growth of 19% to INR 57 crores in Q1 FY26
- As per IQVIA Mat Jun'25 data, Razel franchise has crossed INR 100 crores as compared to INR 69 crores in MAT Jun'23
- As per IQVIA MAT Jun'25 data, Azmarda sales was at INR 75 crores v/s INR 69 crores in MAT Jun'24

International Business Q1 FY26 vs Q1 FY25

- International business recorded revenue of INR 416 crores vs INR 409 crores registering growth of 2%
- International formulations business registered YoY decline of 2% to INR 283 crores vs INR 290 crores
 - While Branded generics exports business recorded growth for Q1 FY26, the other businesses viz. Russia, US & South Africa remained flat or marginally declined for the quarter
- CDMO business registered growth of 8% to INR 115 crores vs INR 106 crores
 - CDMO business momentum to continue
- API business grew to INR 18 crores from INR 13 crores recording YoY growth of 38%

Registered Office:

J.B. Chemicals & Pharmaceuticals Limited,
CIN: L24390MH1976PLC019380
Neelam Centre, 'B' Wing, 4th Floor, Hind Cycle Road,
Worli, Mumbai – 400030, T:+91 22 24822222

Corporate Office:

J.B. Chemicals & Pharmaceuticals Limited,
CIN: L24390MH1976PLC019380
Cnergy IT Park, Unit A, 8th Floor, Appa Saheb Marathe Marg,
Prabhadevi, Mumbai – 400025, T:+91 22 24395200/5500

www.jbpharma.com



GOOD PEOPLE
for **GOOD HEALTH**

About JB Pharma

J.B. Pharma (BSE: 506943 | NSE: JBCHEPHARM | ISIN: INE572A01028), established in 1976, is one of the fastest growing pharmaceutical companies in India and a leading player in the hypertension segment. Besides its strong India presence, which accounts for majority of its revenue, its other two home markets are Russia and South Africa. In India, the company has six brands among the top 300 IPM brands in the country. The company exports its finished formulations to over 40 countries including the USA. Besides supplying branded generic formulations to several countries, it is also a leader in the manufacturing of medicated lozenges. The company ranks amongst the top 5 manufacturers globally in medicated and herbal lozenges. It has eight state of the art manufacturing facilities in India including a dedicated manufacturing facility for lozenges. The manufacturing facilities are certified by leading regulators across the world.

For more details on J.B. Pharma, please visit www.jbpharma.com

For details of our latest sustainability report, please visit <https://jbpharma.com/sustainability-report/>

Media Contact

Mr. Harsh Sheth
MSL Group
Tel: +91 9870631557
Email : harsh.sheth@mslgroup.com

Investor Contact

Mr. Sidharth Ragnekar / Ms. Shruti Joshi
CDR India
Tel : +91 976 991 9966/ +91 750 656 7349
Email : siddharth@cdr-india.com
Shruti@cdr-india.com

Registered Office:

J.B. Chemicals & Pharmaceuticals Limited,
CIN: L24390MH1976PLC019380
Neelam Centre, 'B' Wing, 4th Floor, Hind Cycle Road,
Worli, Mumbai – 400030, T:+91 22 24822222

Corporate Office:

J.B. Chemicals & Pharmaceuticals Limited,
CIN: L24390MH1976PLC019380
Cnergy IT Park, Unit A, 8th Floor, Appa Saheb Marathe Marg,
Prabhadevi, Mumbai – 400025, T:+91 22 24395200/5500



www.jbpharma.com